Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inari Medical Inc (NQ: NARI )

45.85 -0.28 (-0.61%)
Streaming Delayed Price Updated: 3:36 PM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Inari Medical Inc

< Previous 1 2 3 4 5 6 7 Next >
Inari Medical Reports Fourth Quarter and Full Year 2022 Financial Results
From Inari Medical, Inc.
Via GlobeNewswire
3 Magnificent Growth Stocks With 38% to 64% Upside Potential, According to Wall Street
Find out why the investment bankers who follow these stocks think they can soar in the near term. 
Via The Motley Fool
Inari Medical to Announce Fourth Quarter and Full Year 2022 Financial Results
From Inari Medical, Inc.
Via GlobeNewswire
Inari Medical to Participate Virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
From Inari Medical, Inc.
Via GlobeNewswire
Analyst Expectations for Inari Medical's Future
Via Benzinga
What 6 Analyst Ratings Have To Say About Inari Medical
Via Benzinga
Analyst Ratings for Inari Medical
Analysts have provided the following ratings for Inari Medical (NASDAQ:NARI) within the last quarter: 
Via Benzinga
Earnings Scheduled For February 27, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million. 
Via Benzinga
Inari Medical Earnings Preview
Via Benzinga
Analyst Ratings for Inari Medical
Via Benzinga
3 Beaten-Down Growth Stocks That I'm Loading Up On in 2023
These stocks are all down by at least 42% from their all-time highs despite impressive performances from their underlying businesses. 
Via The Motley Fool
Inari Medical Announces First Patient Enrolled in the DEFIANCE Trial, Randomized Controlled Trial Evaluating Clinical Outcomes of the ClotTriever® System in Deep Vein Thrombosis
From Inari Medical, Inc.
Via GlobeNewswire
Inari Medical Announces Preliminary 2022 Revenue and 2023 Guidance
From Inari Medical, Inc.
Via GlobeNewswire
3 Remarkable Growth Stocks That Could Climb 39% to 46%, According to Wall Street
These companies are reporting financial results that aren't being reflected in their stock market performances. 
Via The Motley Fool
Where Inari Medical Stands With Analysts
Analysts have provided the following ratings for Inari Medical (NASDAQ:NARI) within the last quarter: 
Via Benzinga
Inari Medical Q1 Earnings Beat Street View, Lifts FY22 Sales Outlook Above Consensus
Via Benzinga
Inari Medical to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Inari Medical, Inc.
Via GlobeNewswire
2 Top Growth Stocks Down 42.6% and 68.5% to Buy Before They Rebound in 2023
These relatively reliable healthcare businesses are performing much better than their beaten-down stock prices would suggest. 
Via The Motley Fool
Inari Medical to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
From Inari Medical, Inc.
Via GlobeNewswire
Inari Medical Reports Third Quarter 2022 Financial Results
From Inari Medical, Inc.
Via GlobeNewswire
Inari Medical Announces In-hospital and 30-day Outcomes from the Fully Enrolled CLOUT Registry and Results from Propensity-Score Matched Comparison of CLOUT vs. ATTRACT
From Inari Medical, Inc.
Via GlobeNewswire
Where Inari Medical Stands With Analysts
Over the past 3 months, 6 analysts have published their opinion on Inari Medical (NASDAQ:NARI) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Inari Medical to Announce Third Quarter 2022 Financial Results
From Inari Medical, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2022
Upgrades 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022
Upgrades 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2022
Upgrades See all analyst ratings upgrades. 
Via Benzinga
Morgan Stanley Maintains Overweight Rating for Inari Medical: Here's What You Need To Know
Morgan Stanley has decided to maintain its Overweight rating of Inari Medical (NASDAQ:NARI) and lower its price target from $108.00 to $93.00. Shares of Inari Medical are trading up 0.74% over the last... 
Via Benzinga
Inari Medical's Return On Capital Employed Insights
Benzinga Pro data, Inari Medical (NASDAQ:NARI) reported Q1 sales of $86.75 million. Earnings fell to a loss of $3.13 million, resulting in a 382.66% decrease from last quarter. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 21, 2022
Upgrades 
Via Benzinga
A Preview Of Inari Medical's Earnings
Inari Medical (NASDAQ:NARI) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Inari... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.